loading
Precedente Chiudi:
$4.90
Aprire:
$4.91
Volume 24 ore:
185.13K
Relative Volume:
0.31
Capitalizzazione di mercato:
$284.92M
Reddito:
$192.64M
Utile/perdita netta:
$2.51M
Rapporto P/E:
18.06
EPS:
0.27
Flusso di cassa netto:
$12.42M
1 W Prestazione:
-4.12%
1M Prestazione:
+3.38%
6M Prestazione:
-4.31%
1 anno Prestazione:
+41.74%
Intervallo 1D:
Value
$4.83
$4.935
Intervallo di 1 settimana:
Value
$4.82
$5.12
Portata 52W:
Value
$3.44
$6.75

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Name
Nome
Vanda Pharmaceuticals Inc
Name
Telefono
202-734-3400
Name
Indirizzo
2200 PENNSYLVANIA AVE NW, WASHINGTON
Name
Dipendente
203
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
VNDA's Discussions on Twitter

Confronta VNDA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
VNDA 4.8741 284.92M 192.64M 2.51M 12.42M 0.27
VRTX 449.74 115.43B 10.63B -479.80M -1.35B 13.33
REGN 749.06 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 589.18 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 248.30 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.17 24.89B 3.30B -501.07M 1.03B 11.54

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-07-11 Iniziato Cantor Fitzgerald Overweight
2022-02-25 Downgrade Jefferies Buy → Hold
2021-05-12 Iniziato BofA Securities Buy
2021-01-14 Downgrade Citigroup Buy → Neutral
2020-10-29 Aggiornamento Citigroup Neutral → Buy
2020-06-09 Downgrade Citigroup Buy → Neutral
2020-03-16 Downgrade Oppenheimer Perform → Underperform
2020-03-12 Aggiornamento Citigroup Neutral → Buy
2019-11-07 Downgrade Citigroup Buy → Neutral
2019-08-01 Aggiornamento Citigroup Neutral → Buy
2019-07-25 Downgrade Stifel Buy → Hold
2018-12-11 Downgrade Oppenheimer Outperform → Perform
2018-12-04 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2018-12-04 Reiterato Jefferies Buy
2018-11-08 Ripresa Jefferies Buy
2018-09-21 Ripresa Oppenheimer Outperform
2018-05-23 Iniziato Citigroup Buy
2018-01-19 Iniziato Seaport Global Securities Buy
2017-09-14 Reiterato Piper Jaffray Overweight
2017-06-27 Ripresa Piper Jaffray Overweight
2017-05-26 Iniziato H.C. Wainwright Buy
2017-04-12 Iniziato Oppenheimer Outperform
2016-11-09 Iniziato Aegis Capital Buy
2016-10-06 Ripresa Jefferies Buy
Mostra tutto

Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie

pulisher
Nov 19, 2024

Long Term Trading Analysis for (VNDA) - Stock Traders Daily

Nov 19, 2024
pulisher
Nov 18, 2024

Vanda Pharmaceuticals director sells $25,863 in stock - Investing.com India

Nov 18, 2024
pulisher
Nov 18, 2024

Vanda Pharmaceuticals director sells $25,863 in stock By Investing.com - Investing.com UK

Nov 18, 2024
pulisher
Nov 17, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat

Nov 17, 2024
pulisher
Nov 14, 2024

New Strong Buy Stocks For November 14th - Barchart

Nov 14, 2024
pulisher
Nov 13, 2024

Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Nigeria

Nov 13, 2024
pulisher
Nov 12, 2024

Vanda Pharmaceuticals to Present at Major Stifel, Jefferies Healthcare Conferences | VNDA Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

BML Capital Management LLC Sells 169,780 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Nov 12, 2024
pulisher
Nov 09, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results - Investing.com India

Nov 08, 2024
pulisher
Nov 08, 2024

Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results By Investing.com - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024
pulisher
Nov 07, 2024

Vanda Pharmaceuticals Inc (VNDA) Quarterly 10-Q Report - Quartz

Nov 07, 2024
pulisher
Nov 07, 2024

Vanda Seeks New Markets for Hetlioz Amid Generic Competition - Sleep Review

Nov 07, 2024
pulisher
Nov 07, 2024

Vanda: Q3 Earnings Snapshot - Middletown Press

Nov 07, 2024
pulisher
Nov 07, 2024

Vanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ... - Yahoo Finance

Nov 07, 2024
pulisher
Nov 06, 2024

Vanda Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results - PR Newswire

Nov 06, 2024
pulisher
Nov 05, 2024

Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve

Nov 05, 2024
pulisher
Nov 05, 2024

Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St

Nov 05, 2024
pulisher
Nov 04, 2024

Analysts Set Expectations for VNDA Q3 Earnings - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Vanda started at buy by H.C. Wainwright, negative enterprise value cited - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

Over 200% Stock UpsideVanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Brokers Issue Forecasts for VNDA FY2024 Earnings - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

Vanda Pharmaceuticals (VNDA) Set to Announce Quarterly Earnings on Wednesday - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

VNDAVanda Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan

Oct 31, 2024
pulisher
Oct 30, 2024

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 - StockTitan

Oct 30, 2024
pulisher
Oct 28, 2024

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Growth in Short Interest - MarketBeat

Oct 28, 2024
pulisher
Oct 24, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com - MarketBeat

Oct 24, 2024
pulisher
Oct 22, 2024

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More - MSN

Oct 22, 2024
pulisher
Oct 21, 2024

Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail

Oct 21, 2024
pulisher
Oct 19, 2024

Vanda Pharma soars as Cycle Pharma reiterates $8/share offer (update) - MSN

Oct 19, 2024
pulisher
Oct 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc.VNDA - PR Newswire

Oct 17, 2024
pulisher
Oct 15, 2024

VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises - Yahoo Finance

Oct 15, 2024
pulisher
Oct 15, 2024

Cycle Pharmaceuticals Makes Bold Move To Acquire Vanda Pharma - Finimize

Oct 15, 2024
pulisher
Oct 15, 2024

Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals - Yahoo Finance

Oct 15, 2024
pulisher
Oct 15, 2024

D.C. drugmaker Vanda rejects another acquisition offer - The Business Journals

Oct 15, 2024
pulisher
Oct 15, 2024

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - BioSpace

Oct 15, 2024
pulisher
Oct 14, 2024

Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer - Reuters

Oct 14, 2024
pulisher
Oct 14, 2024

Vanda Pharmaceuticals Rejects Deal Proposal From Cycle Group - MarketWatch

Oct 14, 2024
pulisher
Oct 14, 2024

Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda - Yahoo Finance

Oct 14, 2024
pulisher
Oct 14, 2024

Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid - Investing.com

Oct 14, 2024

Vanda Pharmaceuticals Inc Azioni (VNDA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):